An infusion of cells from a child’s own umbilical cord blood seems to boost brain connectivity and motor function in children with spastic cerebral palsy, Duke University research demonstrates.
The placebo-controlled, phase two clinical trial included 63 children with varied types and severities of spastic cerebral palsy, a condition usually caused by brain damage before or at birth.
Children who received one intravenous dose of at least 25 million stem cells per kilogram of their body weight saw improvements in motor function a year later that were greater than those typically observed for children of similar age and condition — and exceeded the gains made by children who received a lower dose of cells or a placebo.
Cord Blood Cell Infusions
Senior author Joanne Kurtzberg, director of Duke University’s Pediatric Blood and Marrow Transplant Program and the Robertson Clinical and Translational Therapy Program, said:
“We are encouraged by the results of this study, which show that appropriately dosed infusions of cord blood cells can help lessen symptoms in children with cerebral palsy. We still have a lot to learn about this therapy so that it can be optimized and accessible to more children with cerebral palsy.
Previous research has indicated it’s safe for children with cerebral palsy to receive an infusion of their own cord blood. Now that we have identified a dosing threshold, we are planning additional studies testing the benefits of multiple doses of cells, as well as the use of donor cells for patients whose own cord blood was not banked.”
Kurtzberg has been a pioneer in testing the therapeutic potential of umbilical cord blood, a rich source of blood stem cells to treat cancers, neurological disorders, and genetic diseases. Cord blood also contains other therapeutic cells that researchers believe could influence the formation of new neural connections in children with cerebral palsy.
Gaining Motor Function
In the cerebral palsy trial, researchers tested doses from 10 million cells per kilogram of body weight up to 50 million cells per kilogram, based on the amount and quality of the cord blood each child had in storage.
Among the tools used to evaluate the children’s progress were MRI to measure brain connectivity and the Gross Motor Function Measure (GMFM-66), a standardized analysis of a child’s ability to crawl, roll, kneel, and complete other movements based on age and development.
Children who have cerebral palsy are expected to gain motor function as they grow and develop and receive traditional therapies, including occupational and physical therapy, says lead author Jessica Sun, a pediatric hematologist-oncologist.
The GMFM-66 attempts to account for this expected growth based on age and the severity of the cerebral palsy, and most participants improved when retested on the GMFM-66 a year after receiving an infusion, even those who received a placebo.
However, the improvements for children who received doses of at least 25 million cells per kilogram of body weight progressed beyond their expected increases when they were tested a year after infusion.
The study had some limitations, including the requirement that participants have cord blood in storage and be able to travel to Duke, both of which required financial means. Being from well-resourced families, most participants were also receiving frequent physical and occupational therapy, Sun says, and those advantages could have influenced the results.
“We are hopeful that cord blood and cell therapy may have a role in treating children with cerebral palsy and brain injury and are encouraged to continue this promising research,”
The work was supported by the Robertson Foundation and The Marcus Foundation.
Sun, J. M., Song, A. W., Case, L. E., Mikati, M. A., Gustafson, K. E., Simmons, R., Goldstein, R., Petry, J., McLaughlin, C., Waters-Pick, B., Chen, L. W., Wease, S., Blackwell, B., Worley, G., Troy, J. and Kurtzberg, J. (2017)
Effect of Autologous Cord Blood Infusion on Motor Function and Brain Connectivity in Young Children with Cerebral Palsy: A Randomized, Placebo-Controlled Trial
Stem Cells Translational Medicine. doi:10.1002/sctm.17-0102
Image: Doc. RNDr. Josef Reischig, CSc. CC BY-SA 3.0